Literature DB >> 8691125

Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes.

J Blake1, J V Johnston, K E Hellström, H Marquardt, L Chen.   

Abstract

Identification of cytolytic T lymphocyte (CTL) epitopes presented by major histocompatibility complex (MHC) class I molecules on tumor cells is critical for the design of active immunotherapy. We describe the use of combinatorial peptide libraries with defined amino acids in two MHC anchor positions to search for epitopes that are recognized by H-2Db- and Kb-restricted CTL specific for the mouse lymphoma EL4. An iterative strategy was used for screening libraries in which 16 amino acids were divided into 3 groups and 3 subgroups: alpha (AL, VT, FY); beta (GS, P, DE); gamma (KR, H, NQ). The proportions of each group and subgroup at individual peptide positions were changed in the library synthesis, and the effect of these changes on CTL activity was measured in a sensitive RMA-S cell assay. A single H-2Db epitope mimic was deduced from the original library that contained > 2 x 10(8) potential peptides and was at least 9 logs more potent than the original library. Immunization of syngeneic mice with this peptide elicited CTL that lysed EL4 cells as well as RMA-S cells pulsed with peptides isolated from Db molecules of EL4 cells, indicating functional similarity between the mimicking peptide and the naturally processed CTL epitope. Furthermore, adoptive transfer of such a CTL line had a therapeutic effect in mice with EL4 established as an ascites tumor. Two H-2Kb-restricted epitope mimics of the same tumor were also identified. Our method represents a novel approach for the construction of MHC class I-restricted targets that can serve as immunogens for active immunotherapy of cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8691125      PMCID: PMC2192679          DOI: 10.1084/jem.184.1.121

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  39 in total

1.  A lymphocyte-specific protein-tyrosine kinase gene is rearranged and overexpressed in the murine T cell lymphoma LSTRA.

Authors:  J D Marth; R Peet; E G Krebs; R M Perlmutter
Journal:  Cell       Date:  1985-12       Impact factor: 41.582

Review 2.  Antigen recognition by class I-restricted T lymphocytes.

Authors:  A Townsend; H Bodmer
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

Review 3.  Generation, translocation, and presentation of MHC class I-restricted peptides.

Authors:  M T Heemels; H Ploegh
Journal:  Annu Rev Biochem       Date:  1995       Impact factor: 23.643

4.  Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides.

Authors:  O Mandelboim; E Vadai; M Fridkin; A Katz-Hillel; M Feldman; G Berke; L Eisenbach
Journal:  Nat Med       Date:  1995-11       Impact factor: 53.440

5.  Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes.

Authors:  E Celis; V Tsai; C Crimi; R DeMars; P A Wentworth; R W Chesnut; H M Grey; A Sette; H M Serra
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

6.  In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation.

Authors:  G Yang; K E Hellström; M T Mizuno; L Chen
Journal:  J Immunol       Date:  1995-10-15       Impact factor: 5.422

7.  Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity.

Authors:  J W Young; K Inaba
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

8.  B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.

Authors:  J V Johnston; A R Malacko; M T Mizuno; P McGowan; I Hellström; K E Hellström; H Marquardt; L Chen
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

9.  Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism.

Authors:  H G Ljunggren; K Kärre
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

10.  Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors.

Authors:  Y Li; K E Hellstrom; S A Newby; L Chen
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

View more
  9 in total

1.  The identification of CD4+ T cell epitopes with dedicated synthetic peptide libraries.

Authors:  H S Hiemstra; G Duinkerken; W E Benckhuijsen; R Amons; R R de Vries; B O Roep; J W Drijfhout
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

2.  Prevalent CD8(+) T cell response against one peptide/MHC complex in autoimmune diabetes.

Authors:  B Anderson; B J Park; J Verdaguer; A Amrani; P Santamaria
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 3.  Tumor antigens discovery: perspectives for cancer therapy.

Authors:  R F Wang
Journal:  Mol Med       Date:  1997-11       Impact factor: 6.354

Review 4.  Recent progress on MHC-I epitope prediction in tumor immunotherapy.

Authors:  Xiangyi Wang; Zhaojin Yu; Wensi Liu; Haichao Tang; Dongxu Yi; Minjie Wei
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

5.  Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells.

Authors:  H Kao; J A Marto; T K Hoffmann; J Shabanowitz; S D Finkelstein; T L Whiteside; D F Hunt; O J Finn
Journal:  J Exp Med       Date:  2001-11-05       Impact factor: 14.307

6.  Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone.

Authors:  B Hemmer; B T Fleckenstein; M Vergelli; G Jung; H McFarland; R Martin; K H Wiesmüller
Journal:  J Exp Med       Date:  1997-05-05       Impact factor: 14.307

7.  Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide.

Authors:  S Tangri; G Y Ishioka; X Huang; J Sidney; S Southwood; J Fikes; A Sette
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

8.  Position-Scanning Peptide Libraries as Particle Immunogens for Improving CD8+ T-Cell Responses.

Authors:  Xuedan He; Shiqi Zhou; Breandan Quinn; Wei-Chiao Huang; Dushyant Jahagirdar; Michael Vega; Joaquin Ortega; Mark D Long; Fumito Ito; Scott I Abrams; Jonathan F Lovell
Journal:  Adv Sci (Weinh)       Date:  2021-10-30       Impact factor: 17.521

Review 9.  Diversity-oriented approaches for interrogating T-cell receptor repertoire, ligand recognition, and function.

Authors:  Michael E Birnbaum; Shen Dong; K Christopher Garcia
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.